Medtronic PLC (MDT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Medtronic PLC stock (MDT) is currently trading at $86.16. Medtronic PLC PE ratio is 24.70. Medtronic PLC PS ratio (Price-to-Sales) is 3.20. Analyst consensus price target for MDT is $111.38. WallStSmart rates MDT as Hold.
Medtronic PLC (MDT) stock price prediction for 2030: Base case $73.53. Bull case $91.91. Bear case $55.15. See full MDT 2030 price forecast and methodology on WallStSmart.
- MDT PE ratio analysis and historical PE chart
- MDT PS ratio (Price-to-Sales) history and trend
- MDT intrinsic value — DCF, Graham Number, EPV models
- MDT stock price prediction 2025 2026 2027 2028 2029 2030
- MDT fair value vs current price
- MDT insider transactions and insider buying
- Is MDT undervalued or overvalued?
- Medtronic PLC financial analysis — revenue, earnings, cash flow
- MDT Piotroski F-Score and Altman Z-Score
- MDT analyst price target and Smart Rating
Medtronic
📊 No data available
Try selecting a different time range
MDT Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Medtronic PLC (MDT)
MDT trades 254% above its Graham fair value of $24.34, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Medtronic PLC (MDT) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, institutional own.. Concerns around return on equity and eps growth. Fundamentals are solid but monitor weak areas for improvement.
Medtronic PLC (MDT) Key Strengths (3)
88.21% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $20 kept per $100 revenue
Supporting Valuation Data
Medtronic PLC (MDT) Areas to Watch (7)
Earnings declining -11.80%, profits shrinking
Low profitability relative to shareholder equity
Modest revenue growth at 8.70%
Growth is fairly priced, not cheap, not expensive
Revenue is fairly priced at 3.20x sales
Fairly priced relative to book value
Decent profitability, keeps $13 per $100 revenue
Medtronic PLC (MDT) Detailed Analysis Report
Overall Assessment
This company scores 56/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 4.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap, Operating Margin. Profitability is solid with Operating Margin at 20.00%.
The Bear Case
The primary concerns are EPS Growth, Return on Equity, Revenue Growth. Some valuation metrics including PEG Ratio (1.55), Price/Sales (3.20), Price/Book (2.31) suggest expensive pricing. Growth concerns include Revenue Growth at 8.70%, EPS Growth at -11.80%, which may limit upside. Profitability pressure is visible in Return on Equity at 9.39%, Profit Margin at 13.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 9.39% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 8.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Market Cap) and negatives (EPS Growth, Return on Equity). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WallStSmart Analysis Synopsis
Data-driven financial summary for Medtronic PLC (MDT) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Medtronic PLC operates as a stable business with moderate growth and solid fundamentals. Revenue reached 35.5B with 9% growth year-over-year. Profit margins of 13.0% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 939.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 2.3B in free cash flow and 2.7B in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Medtronic PLC push profit margins above 15% as the business scales?
Dividend sustainability with a current yield of 3.2%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Medtronic PLC.
Bottom Line
Medtronic PLC offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(14 last 3 months)
| Insider | Type | Shares |
|---|---|---|
PIETON, THIERRY EVP & Chief Financial Officer | Sell | -2,976 |
| Insider | Type | Shares |
|---|---|---|
BLOMQUIST, DENISE L. Chief Accounting Officer | Sell | -340 |
| Insider | Type | Shares |
|---|---|---|
BLOMQUIST, DENISE L. Chief Accounting Officer | Sell | -148 |
Data sourced from SEC Form 4 filings
Last updated: 8:16:13 AM
About Medtronic PLC(MDT)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.